Clinical Trial Detail

NCT ID NCT03712605
Title Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

Merkel cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.